Molecules 2011, 16(10), 8475-8503; doi:10.3390/molecules16108475
Review

Pharmacological and Biological Antiviral Therapeutics for Cardiac Coxsackievirus Infections

1 Department of Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, Gustav-Meyer-Allee 25, 13355 Berlin, Germany 2 Department of Cardiology & Pneumology, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
* Author to whom correspondence should be addressed.
Received: 25 August 2011; in revised form: 29 September 2011 / Accepted: 30 September 2011 / Published: 11 October 2011
(This article belongs to the Special Issue Antivirals)
PDF Full-text Download PDF Full-Text [998 KB, uploaded 11 October 2011 12:02 CEST]
Abstract: Subtype B coxsackieviruses (CVB) represent the most commonly identified infectious agents associated with acute and chronic myocarditis, with CVB3 being the most common variant. Damage to the heart is induced both directly by virally mediated cell destruction and indirectly due to the immune and autoimmune processes reacting to virus infection. This review addresses antiviral therapeutics for cardiac coxsackievirus infections discovered over the last 25 years. One group represents pharmacologically active low molecular weight substances that inhibit virus uptake by binding to the virus capsid (e.g., pleconaril) or inactivate viral proteins (e.g., NO-metoprolol and ribavirin) or inhibit cellular proteins which are essential for viral replication (e.g., ubiquitination inhibitors). A second important group of substances are interferons. They have antiviral but also immunomodulating activities. The third and most recently discovered group includes biological and cellular therapeutics. Soluble receptor analogues (e.g., sCAR-Fc) bind to the virus capsid and block virus uptake. Small interfering RNAs, short hairpin RNAs and antisense oligonucleotides bind to and led to degradation of the viral RNA genome or cellular RNAs, thereby preventing their translation and viral replication. Most recently mesenchymal stem cell transplantation has been shown to possess antiviral activity in CVB3 infections. Taken together, a number of antiviral therapeutics has been developed for the treatment of myocardial CVB infection in recent years. In addition to low molecular weight inhibitors, biological therapeutics have become promising anti-viral agents.
Keywords: coxsackievirus; myocarditis; soluble receptors; RNA interference; antiviral drugs

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Fechner, H.; Pinkert, S.; Geisler, A.; Poller, W.; Kurreck, J. Pharmacological and Biological Antiviral Therapeutics for Cardiac Coxsackievirus Infections. Molecules 2011, 16, 8475-8503.

AMA Style

Fechner H, Pinkert S, Geisler A, Poller W, Kurreck J. Pharmacological and Biological Antiviral Therapeutics for Cardiac Coxsackievirus Infections. Molecules. 2011; 16(10):8475-8503.

Chicago/Turabian Style

Fechner, Henry; Pinkert, Sandra; Geisler, Anja; Poller, Wolfgang; Kurreck, Jens. 2011. "Pharmacological and Biological Antiviral Therapeutics for Cardiac Coxsackievirus Infections." Molecules 16, no. 10: 8475-8503.

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert